High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients
- PMID: 1675892
- DOI: 10.1016/0006-3223(91)90132-6
High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients
Abstract
We investigated whether the lack of therapeutic response to long-term and adequate neuroleptic treatment was due to a failure to achieve a blockade of cerebral dopamine receptors. Six chronic schizophrenic and medicated patients (DSM-III-R diagnosis, paranoid or disorganized type) were assessed with the Present State Examination and the Brief Psychiatric Rating Scale. According to the Chouinard Rating Scale there were little extrapyramidal symptoms, although no anticholinergic drugs were given. Plasma levels of the neuroleptics were determined and found in the therapeutic range or higher. Dopamine D2-receptor occupancy was determined with positron emission tomography using 11C-methylspiperone as ligand. There was a more than 95% blockade of the D2 receptors in the striatum. These results indicate that the lack of therapeutic response and extra-pyramidal side effects cannot be attributed to an incomplete blockade of cerebral D2 receptors and that the pathogenetic role of these receptors can be questioned in therapy-resistant schizophrenic patients.
Similar articles
-
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.Am J Psychiatry. 1999 Jun;156(6):869-75. doi: 10.1176/ajp.156.6.869. Am J Psychiatry. 1999. PMID: 10360125 Clinical Trial.
-
Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.Biol Psychiatry. 1993 Feb 15;33(4):227-35. doi: 10.1016/0006-3223(93)90288-o. Biol Psychiatry. 1993. PMID: 8097114 Clinical Trial.
-
Striatal dopamine D2 receptors in tardive dyskinesia: PET study.J Neurol Neurosurg Psychiatry. 1989 Nov;52(11):1248-52. doi: 10.1136/jnnp.52.11.1248. J Neurol Neurosurg Psychiatry. 1989. PMID: 2574230 Free PMC article.
-
Implications of brain imaging for the management of schizophrenia.Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S15-20. doi: 10.1097/00004850-199803003-00003. Int Clin Psychopharmacol. 1998. PMID: 9690965 Review.
-
Recent developments in PET scan imaging of neuroreceptors in schizophrenia.Isr J Psychiatry Relat Sci. 1995;32(1):22-9. Isr J Psychiatry Relat Sci. 1995. PMID: 7622344 Review.
Cited by
-
Factors associated with response to clozapine in schizophrenia: a review.Psychopharmacol Bull. 2011;44(1):32-60. Psychopharmacol Bull. 2011. PMID: 22506438 Free PMC article. Review.
-
White matter changes in treatment refractory schizophrenia: Does cognitive control and myelination matter?Neuroimage Clin. 2018 Jan 28;18:186-191. doi: 10.1016/j.nicl.2018.01.010. eCollection 2018. Neuroimage Clin. 2018. PMID: 29387534 Free PMC article.
-
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.Neurobiol Dis. 2019 Nov;131:104257. doi: 10.1016/j.nbd.2018.08.016. Epub 2018 Aug 29. Neurobiol Dis. 2019. PMID: 30170114 Free PMC article. Review.
-
D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.J Neural Transm Gen Sect. 1995;99(1-3):173-85. doi: 10.1007/BF01271477. J Neural Transm Gen Sect. 1995. PMID: 8579803 Review.
-
Differential Role of Active Compounds in Mitophagy and Related Neurodegenerative Diseases.Toxins (Basel). 2023 Mar 6;15(3):202. doi: 10.3390/toxins15030202. Toxins (Basel). 2023. PMID: 36977093 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical